Astrana Health (ASTH) EBITDA Margin (2010 - 2026)

Astrana Health has disclosed EBITDA Margin across 17 years of filings, most recently posting 2.96% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 2.96%, down 36.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.46% (down 308.0% YoY), and the FY2025 annual result was 0.26%, down 413.0% from the prior year.
• EBITDA Margin came in at 2.96% for Q1 2026 at Astrana Health, up from 5.45% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 15.8% in Q3 2022 to a low of 5.45% in Q4 2025.
• The 5-year median for EBITDA Margin is 5.7% (2022), against an average of 5.05%.
• Peak annual rise in EBITDA Margin reached 312 bps in 2022, while the deepest fall reached 760 bps in 2022.
• Astrana Health's EBITDA Margin stood at 4.28% in 2022, then slumped by 126 bps to 1.1% in 2023, then surged by 110 bps to 0.11% in 2024, then plunged by 5136 bps to 5.45% in 2025, then jumped by 154 bps to 2.96% in 2026.
• The last three EBITDA Margin figures came in at 2.96% (Q1 2026), 5.45% (Q4 2025), and 2.01% (Q3 2025), per Business Quant data.